ArchiMed announced that it will acquire Esperion Therapeutics for approximately $1.1 billion.
Esperion shareholders will receive $3.16 per share in cash at closing, plus the right to participate in contingent milestone payments of up to $100 million in the aggregate tied to future net sales performance. The upfront cash consideration represents a premium of 58% to Esperion’s closing share price on April 30, 2026.
Esperion Therapeutics is a biotechnology company that focuses on the discovery and development of therapies using high-density lipoprotein, or -good- cholesterol, for treating cardiovascular disease. Esperion reported full-year 2025 revenue of $403.1 million.
ArchiMed is an independent private equity investment firm focused exclusively on the healthcare industry. It has directly managed and invested in more than 80 companies with a combined value of $50 billion. Its mix of operational, medical, scientific and financial expertise allows the ArchiMed team to serve as a strategic and financial partner to European and North American small and middle-market businesses.
Following completion of the transaction, Esperion will become a privately held company, and its common stock will no longer be listed on the Nasdaq. Debt financing will be provided by investment funds managed by Pharmakon Advisors, LP. The transaction is not subject to a financing condition.
Moelis & Company LLC is acting as exclusive financial advisor to ArchiMed and Sidley Austin LLP is serving as legal advisor. Centerview Partners is acting as exclusive financial advisor to Esperion and Goodwin Procter LLP is serving as legal advisor. Akin Gump LLP is serving as legal advisor to Pharmakon Advisors.
According to data captured in the LevinPro HC database, this marks the 50th Biotechnology transaction of the year. It is also ArchiMed’s first deal of the year. In 2025 it acquired Arkstone Medical Solutions, a biotechnology company providing clinical decision support powered by machine learning and artificial intelligence, helping healthcare providers optimize antimicrobial use.
